TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have completed Study SPD422 308

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SPD422 (anagrelide hydrochloride) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients will be enrolled in the study if they fulfill the following three inclusion criteria:~1. Protocol criteria for HAP/VAP: Criteria for making a correct diagnosis of HAP will be met if the patient develops a new or progressive pulmonary infiltrate associated with at least two of the following: new or increased respiratory symptomatology (cough, sputum or tracheal secretions, shortness of breath), fever or hypothermia, leukocytosis, left shift, or leukopenia, or deterioration of pulmonary function.~2. Isolation of MRSA from a respiratory sample or blood culture within 48 hours of the diagnosis of HAP/VAP~3. Treatment of MRSA HAP/VAP with either vancomycin or linezolid with incorporation of 100 patients in the vancomycin arm and 100 patients in the linezolid arm~Exclusion Criteria:~Patients not meeting enrollment criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linezolid observational cohort (Type: None): None
- Vancomycin observational cohort (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of the NeuroSENSE for Monitoring the Hypnotic Depth of Anesthesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age 18-75 years~* ASA (American Society of Anesthesiologist) physical status I, II, or III~* ability to read and understand the informed consent form~* undergoing anesthesia procedure requiring intubation~* scheduled to undergo either open or laparoscopic abdominal surgical procedures (e.g. colectomy, hysterectomy, radical retropubic prostatectomy, nephrectomy, pancreatectomy, etc.), breast surgery including reduction, reconstruction and mastectomies, or orthopedic surgeries under general anesthesia, expected to last at least 1 hour.~Exclusion Criteria:~* history of major head injury (possible abnormal EEG)~* acquired scalp or skull abnormalities (e.g. psoriasis, eczema, angioma, scar tissue, burr holes, cranial implants)~* evidence of recent trauma or active neurological disorder, stroke, seizure disorder, intellectual disability, dementia or diagnosis of Alzheimer's disease~* major antipsychotic medications taken within last 7 days (eg. Lithium, risperidone, olanzapine)~* known history of alcohol or drug abuse within last 30 days~* body mass index (weight in kilograms divided by square of height in meters) \> 40.0 kg/m2~* uncontrolled hypertension with blood pressure recorded prior to surgery (systolic blood pressure \> 200 mmHg or diastolic blood pressure \> 110 mmHg)~* systolic blood pressure \< 90 mmHg, recorded prior to surgery~* heart rate (HR) \< 45 beats/min, recorded prior to surgery~* insulin-dependent diabetes mellitus~* pregnancy~* any serious medical condition that would interfere with cardiovascular response assessment or study results interpretation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Anesthesia (Type: None): A single study group undergoing general anesthesia procedure to observe post-hoc the effect on the NeuroSENSE monitor readings.~Interventions of interest:~Drug: Propofol induction followed by randomized doses of desflurane; Emergence by stepping down the desflurane ET - See intervention descriptions.~Device: Recording of EEG using NeuroSENSE (blinded to clinicians) - See intervention descriptions.~Other: Data Collection - See intervention descriptions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 to 60 years of age, who have ADPKD with an estimated glomerular filtration rate (eGFR) of 60 ml/min/1.73m2 or above~Exclusion Criteria:~1. Patients on chronic use of medications known to affect AVP secretion (Serotonin Specific Reuptake inhibitors (SSRI), Opioids, Tricyclic Antidepressants (TCA) and Tolvaptan)~2. History of diseases influencing renal concentration capacity, such as, diabetes insipidus, adrenal or thyroid deficiencies, present or prior use of lithium, or kidney diseases other than ADPKD.~3. Baseline hyponatremia (Na below 135 mEq/l)~4. Inability to comply with dietary or fluid requirements~5. Have physical or cognitive impairments which prevent participation~6. Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Diet and Water adjustment (Type: ACTIVE_COMPARATOR): Reduction in dietary salt and protein intake
- Control (Type: NO_INTERVENTION): Continue with usual diet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PoCUS Guided Fluids to Prevent Post-induction Hypotension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70 years~* Elective surgery~* IVC-CI ≥ 43% on their preoperative POCUS scan.~Exclusion Criteria:~* Hypotension, defined as MAP below 65 mmhg, prior to the induction of general anesthesia.~* Treated with angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) on the day of surgery.~* Patients with heart failure with ejection fraction (EF) \< 40%.~* Patients with documented acute or chronic renal failure.~* Patients with neuraxial blockade (epidural or spinal) performed before induction of general anesthesia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fluid Bolus (FB+) (Type: ACTIVE_COMPARATOR): Patients in the FB+ group will receive a single bolus of 500 ml of Ringer's Lactate over 5-10 minutes.
- Non fluid bolus (FB-) (Type: PLACEBO_COMPARATOR): Patients in the FB- group will not receive a fluid bolus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes mellitus (diet and exercise treated, or treated with specific oral antidiabetics (metformin, sulfonylureas and glinides) mono- or combination therapy) diagnosed at least 3 months previously~* BMI between 18.5 and 40 kg/m2~* HbA1c between 6.5 and 10.0% both inclusive~Exclusion Criteria:~* Known or suspected allergy to trial products or related products~* Previous participation in this trial (randomised). Re-screening of screening failures is allowed only once~* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptives are defined as combination oral contraceptives (OC), hormonal intra uterine devices (IUDs), implants and injectables; for Germany, a condom for the male partner must be used in combination with OC, IUD, implant or injectables for the duration of the trial and for 30 days following the last dose of trial medication) if not sterile or post-menopausal~* The receipt of any investigational drug within 3 months prior to this trial~* Previous insulin treatment (short-term insulin treatment of up to 7 days are exempted if this has occurred no later than 3 months prior to screening).~* Cancer (except basal cell skin cancer or squamous cell skin cancer) or any clinically significant disorder (except type 2 diabetes)~* Clinically significant active cardiovascular disease including history of myocardial infarction (heart attack) within the past 6 months and/or heart failure at the discretion of the Investigator.~* History of alcoholism or drug abuse during the last 12 months~* Blood donation within the last 3 months. Plasma donation within the last month.~* Additional exclusion criteria for Germany: Male subjects who are sexually active and have partners who are or could be pregnant, not using a barrier method of contraception (e.g. condom) for the duration of the trial and for 30 days following the last dose of trial medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages: 21 to 80~2. Microscopically confirmed premalignant oral epithelial disease~3. No previous history of cancer (with the exception of basal cell carcinoma of the skin)~4. Tobacco free for at least six weeks prior to entrance in the trial and remain tobacco-free for the three month duration of the study~5. Availability for necessary study follow-up evaluations (every 10 to 14 days during the trial)~6. Capable of providing informed consent.~Exclusion Criteria:~1. Previous history of cancer (with the exception of basal cell carcinoma of the skin)~2. Current use of tobacco products or refusal to remain tobacco-free for the three month duration of the study~3. Lack of microscopically confirmed premalignant oral epithelial changes~4. Microscopic diagnosis of oral squamous cell carcinoma~5. Previous history of radiation therapy on same side of the head and neck region~6. History of allergy to any kind of berry~7. Women who are determined to be pregnant or plan to be pregnant during the trial~8. Women who are nursing.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 10% FBR containing bioadhesive gel (Type: ACTIVE_COMPARATOR): Drug consisting of 10% FBR containing bioadhesive gel. Participants instructed to apply 0.5 gm of 10% FBR containing bioadhesive gel four times a day to lesional site
- Placebo Gel (Type: PLACEBO_COMPARATOR): Color/consistency matched placebo (no black raspberry) gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients either non-neutropenic with absolute neutrophil counts \>= 500 cells/mm3 or neutropenic with absolute neutrophil counts \< 500 cells/mm3 must have:~* Candidemia or invasive candidiasis,~* Confirmation and typical clinical signs and symptoms by fungal culture and/or histology,~* Positive culture obtained no more than four days prior to the first dose of study medication.~Exclusion Criteria:~* Patient is pregnant or nursing~* Patients with evidence of liver disease as defined by: a) SGOT/AST or SGPT/ALT \> 10 times the upper limit of normal (ULN); or b) Total bilirubin \> 5 times ULN.~* Patients whose sole diagnosis is oropharyngeal and/or esophageal candidiasis and/or with positive cultures of urine specimens, sputum specimens, bronchoalveolar-lavage specimens or samples from indwelling drains.~* Patients who have received prophylactic/empiric therapy with azoles or conventional amphotericin B for more than three days within one week prior to enrollment. Neutropenic patients, however, may have received prophylactic azoles without time restrictions.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Music Therapy in Obsessive Compulsive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* were at least 18 years or older;~* had axis I diagnosis of OCD according to the criteria delineated by the diagnostic and statistical manual of mental disorders - fourth edition diagnosed by an experienced psychiatrist~* had not received treatment previously for the disorder~* agreed to partake in the study~Exclusion Criteria:~* refused to partake in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard treatment + music therapy (Type: ACTIVE_COMPARATOR): Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy. Music therapy encompassing 12 half-hour sessions of therapist-supervised receptive music therapy scheduled over four weeks
- Standard treatment only (Type: ACTIVE_COMPARATOR): Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Correlation of Several Formulas to Evaluate Insulin Sensitivity With the Predicted M Index

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Both genres~* Age 30 to 60 years~* BMI \<25 kg / m2,~* Patients who are not sedentary or who participate in heavy physical activities~* Stable weight in the last 3 months~Exclusion Criteria:~* Blood pressure \>120/80 mmHg~* Glucose \>100 mg/dL~* Postprandial glucose \>140 mg/dL~* Cholesterol \>200 mg/dL~* Triglycerides \>150 mg/dL~* Smoking~* Women with polycystic ovarian syndrome~* History of metabolic, cardiovascular, thyroid, renal, pancreatic and/or arterial hypertension~* Use of medications that modify insulin sensitivity (corticosteroids)~* Previous surgery or infection~* Symptoms of vomiting and/or excessive nausea

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Healthy individuals (Type: None): Cross-Sectional. No intervention. Patients of both sexes who are not sedentary or who participate in heavy physical activities and residents of the metropolitan area of Guadalajara

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Celecoxib In Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Volunteers~Exclusion Criteria:~* Endoscopic evidence of ulceration, erosion or active bleeding etc. in the esophagus, stomach, pylorus and/or duodenum prior to treatment endoscopy~* A history of gastrointestinal ulcer~* Any use of celecoxib, nonsteroidal anti-inflammatory drugs (including aspirin), anti-ulcer medication, antacids, systemic steroids or antibiotics within four weeks prior to the first dose of study medication

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Celecoxib (Type: EXPERIMENTAL): None
- Loxoprofen (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Survivors After Botulism Outbreak

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusions:~* Ate the bamboo shoots in Banluang district, on March,14 2006~* Clinical of respiratory failure and need ventilator assistant~* Needed to referred to other hospital~* The staffs of referred hospital willing to participate in the Thai Botulism study group~Exclusion Criteria:~* Patients who did not eat bamboo shoots in Banluang district on March14,2006.~* No clinical of respiratory failure.~* Not referred to other hospital.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Efficacy and Safety of Substrate Ablation of Monomorphic Ventricular Tachycardia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ischemic cardiomyopathy, with ischemic myocardial scar~* Sustained monomorphic ventricular tachycardia~* Age \> 18 years~* Prior ICD implantation~Exclusion Criteria:~* VT storm~* NYHA functional class IV~* Additional indication for antiarrhythmic drug therapy~* Contraindication for both study drugs (amiodarone and sotalol).~* Uncontrolled myocardial ischemia.~* LV thrombus.~* Non-ischemic VT substrate.~* Contraindications for anticoagulation.~* Prior substrate ablation in the previous 6 months~* Cr \> 2.5 mg/dL~* Mitral AND aortic mechanical valvular prosthesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ablation (Type: EXPERIMENTAL): Substrate-based radiofrequency catheter ablation
- Antiarrhythmic drug therapy (Type: ACTIVE_COMPARATOR): Antiarrhythmic drug therapy; amiodarone or sotalol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of High Dose MHAA4549A in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older~* Body mass index (BMI) between 18 and 32 kg/m2, inclusive~* Weight 40 - 100 kg~* In good health, determined by no clinically significant findings from medical history, 12-lead ECG, vital signs, and clinical laboratory evaluations~* Willing to use acceptable contraceptive measures as defined by the protocol~* Agreeable to, and deemed able to by the investigator, to comply with the requirements of the study, including the follow-up period~* Willing to abstain from the use of drugs of abuse while enrolled in the study~Exclusion Criteria:~* History or clinically significant manifestations of disorders~* History of acute allergic reaction or drug allergies~* History or presence of an abnormal ECG~* History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit~* History of significant drug abuse within 1 year prior to screening~* Current tobacco smokers~* Positive drug screen at screening or at check-in~* Positive pregnancy test result at screening or Day -1 or breast feeding during the study~* Males who have a pregnant female partner~* Donation of plasma within 7 days prior to study drug administration~* Donation or loss of whole blood~* Receipt of blood products within 2 months before initiation of dosing on Day 1~* History of malignancy within 10 years of screening except completely excised basal cell carcinoma or squamous cell carcinoma of the skin~* History of severe systemic bacterial, fungal, or parasitic infections associated with more than two hospitalizations per year or more than two courses of intravenous (IV) antibiotics within 1 year~* Received oral antibiotics within 4 weeks before initiation of dosing on Day 1, or IV antibiotics within 8 weeks before initiation of dosing~* Hospitalization within 4 weeks before initiation of dosing on Day 1~* Use of any over the counter or prescription medications/products within 7 days prior to Day 1 and unwilling to abstain from the use of such drugs up until at least the Day 29 study visit, unless deemed acceptable by the investigator and Sponsor~* Participation in a clinical trial within 4 weeks~* Received any vaccine within 14 days prior to screening~* Positive blood test for chronic viral infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- MHAA4549A higher dose (Type: EXPERIMENTAL): None
- MHAA4549A lower dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete